MESO logo

Mesoblast Limited American Depositary Shares

MESO

MESO: Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.

more

Show MESO Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of MESO by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by MESO's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Methods for increasing osteoblastic function Oct. 05, 2021
  • Patent Title: Method of treating graft versus host disease Dec. 01, 2020
  • Patent Title: Methods of treating or preventing respiratory conditions Jun. 23, 2020
  • Patent Title: Methods of treating or preventing rheumatic disease Mar. 24, 2020
  • Patent Title: Method of increasing proliferation of bone marrow mononuclear cells expressing stro1- Jan. 28, 2020
  • Patent Title: Perivascular mesenchymal precursor cells Sep. 24, 2019
  • Patent Title: Mesenchymal precursor cell Mar. 05, 2019
  • Patent Title: Methods of treating multiple sclerosis using stro-1+ and tnap+ multipotential cells Feb. 19, 2019
  • Patent Title: Methods for treating obesity and/or metabolic syndrome Dec. 25, 2018
  • Patent Title: Method of treating graft versus host disease Oct. 23, 2018
  • Patent Title: Methods of treating or preventing respiratory conditions Jul. 24, 2018
  • Patent Title: Methods of treating or preventing rheumatic disease May. 22, 2018
  • Patent Title: Method for treating or preventing a pancreatic dysfunction May. 15, 2018
  • Patent Title: Methods for increasing osteoblastic function May. 09, 2017
  • Patent Title: Production of reprogrammed pluripotent cells Nov. 08, 2016
  • Patent Title: Method for treating diabetic renal failure or syndrome x Nov. 01, 2016
  • Patent Title: Expansion of haemopoietic precursors Aug. 16, 2016
  • Patent Title: Methods for treating obesity and/or metabolic syndrome Jul. 12, 2016
  • Patent Title: Methods of generating, repairing and/or maintaining connective tissue in vivo Jul. 05, 2016
  • Patent Title: Method of treating graft versus host disease Apr. 05, 2016
  • Patent Title: Methods of treating or preventing rheumatic disease Feb. 23, 2016
  • Patent Title: Perivascular mesenchymal precursor cell induced blood vessel formation Nov. 03, 2015
  • Patent Title: Perivascular mesenchymal precursor cell induced blood vessel formation Oct. 27, 2015
  • Patent Title: Monoclonal antibody stro-4 Jul. 28, 2015
  • Patent Title: Method for treating or preventing a pancreatic dysfunction Nov. 25, 2014
  • Patent Title: Repair and/or reconstitution of invertebral discs Oct. 14, 2014
  • Patent Title: Expansion of haemopoietic precursors Sep. 09, 2014
  • Patent Title: Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase Feb. 05, 2013
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of MESO in WallStreetBets Daily Discussion

MESO News

Recent insights relating to MESO

CNBC Recommendations

Recent picks made for MESO stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MESO

Corporate Flights

Flights by private jets registered to MESO